We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vectura Group Plc | LSE:VEC | London | Ordinary Share | GB00BKM2MW97 | ORD 0.0271P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 164.80 | 164.80 | 165.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
07/9/2017 12:02 | Now would be an appropriate time for the directors to show a little skin in the game. If they are not fully committed then why should we be? | jimboyce | |
07/9/2017 11:43 | SP getting decimated! Bleeding PnL and losing confidence. | letsmakesome | |
07/9/2017 11:42 | Looks like may have called that wrong but very difficult to catch the bottom.11:42am | pooroldboy55 | |
07/9/2017 10:32 | just dipped my toe in with 2000@91.6 lets keep fingers crossed. Still have 40000 from skp buy out at av 74p. | pooroldboy55 | |
07/9/2017 10:27 | Just topped up my ISA with 10K @ 91.1. Lets hope in 6 months time it's back to where it should be - sub 150 !! | ropey | |
07/9/2017 09:36 | Would be tempted to buy some if only had some idea what the bottom is will it go below 90p????? | pooroldboy55 | |
07/9/2017 09:25 | Vectura Group PLC VEC Numis Buy 91.15 95.00 - 205.00 Reiterates Just released | justiceforthemany | |
07/9/2017 09:15 | I can see the likes of Mundipharma or Takeda taking this amateurishly managed company out at these levels. | cumnor | |
07/9/2017 09:13 | Agree justice none of it makes sense but that's the markets for you also think sell off is way over done POB. | pooroldboy55 | |
07/9/2017 08:56 | What anyone writes on this board has no effect on the share price so lets be sensible and stick to the 'facts'. Product sales and recurring revenue was up strongly on the same period last year. >25% in fact. That is very encouraging. To repeat the headline wider loss was due to a write down of intangible assets. Now the balance sheet is still incredibly strong with equity of >£650M and an equity ratio of >5 Most companies are around the 1-1.5 mark if that The higher the better so >5 is excellent as is the cash balance of >£90M. Trading at 5 year lows and BELOW BOOK VALUE | justiceforthemany | |
07/9/2017 08:28 | The way things are going will be back at 50p like it was 7 years ago . | pooroldboy55 | |
07/9/2017 08:22 | Why would someone hold shares at 190p to go to 160p? | andysaw | |
07/9/2017 08:14 | Any new recommendations from brokers ? I saw only Hold with target 160p from Peel Hunt | a1ord53 | |
06/9/2017 21:17 | What is important is that the underlying business is PROFITABLE. This is a classic example of looking past the headlines and analysing the books. Take out the exceptionals and the intangibles write down and you are looking at a projected full year profit of around £40M | justiceforthemany | |
06/9/2017 21:05 | Operating losses rose as a result of £53.3m worth of amortisation of intangible assets related to last year's £441m merger with Skyepharma. We don't know what else will come out in the next update. This loss is disclosed along with the delay in approval due to outstanding issues. Things don't look good as of yet. | andysaw | |
06/9/2017 21:00 | For a drug company to be trading below book value is very rare. GSK and others trade at as many as times as 15x book value. Predators may swoop given this and the healthy cash balance. | justiceforthemany | |
06/9/2017 20:58 | No andysaw the loss is solely due to a write down in intangible assets of £53M. Sure we should question why those were written down but hopefully just a one off and no repeat in H2. | justiceforthemany | |
06/9/2017 20:57 | Prior to that, the analyst said, Vectura had only highlighted the risks attached to the drug as "Disruption to the launch of VR315 (US)".In today's results, however, van Dulken pointed out, Vectura formally downgraded this to: "Issues raised by the US FDA in their Complete Response Letter for VR315 (US) are not resolved. Failure to resolve these issues at all or in a timely manner will result in a loss of potential future revenues for the Group as well as additional funds for investment.""We expect to be able to confirm the regulatory timetable before the end of the year".Van Dulken concluded that "pipeline uncertainty is never good, especially for smaller companies for whom success and/or failure can hinge on a select few drugs compared to more diverse revenue streams at bigger Pharma counterparts." | andysaw | |
06/9/2017 20:50 | Bring back SKP, all is forgiven!!! ... ;-) nearly 1 1/2 yrs after the merger, I wasn't expecting to see the share price of the combined group to halve.. | sikhthetech | |
06/9/2017 20:42 | 44.5m is a very big loss for an interim update especially the sector is under pressure. Also I hope they don't come up with a profit warning soon as it seems to be the latest trend. I reckon it will fall to 80p in next few days and shorters may have increased the shorts after this news. | andysaw | |
06/9/2017 20:29 | Well I bought some more at 98. Who dares wins. | richtea2517 | |
06/9/2017 20:03 | There's no point the market would look at is as a bit of a gimmick. Have been a holder of BTG since early 2000's there was mention that they were thee to four years away from paying there first dividend! That was about 2007 and I would say we're about three to for years away still. | dp1umb | |
06/9/2017 19:27 | What even a small one e.g. 0.5p/share? Would cost only £3.5M/year and gives a little back to loyal suffering shareholders. Awful decision by management. What do they get paid for? | justiceforthemany | |
06/9/2017 19:08 | At least three years away from a dividend. | dp1umb |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions